Improvement of This Program Helps Aclarion’s Dedication to Lead With Sturdy Scientific Proof and Interact the Payer Group By means of Key Opinion Chief Advocacy
Aclarion to Take part in Upcoming ISASS 2023 on June 1-3, 2023 in San Francisco, CA The place Their Health Economics Outcomes Summary Will probably be Offered
BROOMFIELD, CO, Could 23, 2023 (GLOBE NEWSWIRE) — by way of NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare expertise firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians determine the situation of continual low again ache, introduced at this time that Dean Karahalios, M.D., Medical Director of Mind & Backbone Institute at Advocate Aurora Health Care in Illinois, will advise the corporate as a key opinion chief (KOL) nationally.
Power low again ache (cLBP) is a number one reason behind opioid dependancy within the U.S. and the only costliest prognosis in the USA. Aclarion’s Nociscan resolution is the primary evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to spotlight if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers vital insights into the situation of a affected person’s low again ache, giving physicians readability to optimize remedy methods.
Dr. Karahalios embraces a philosophy of care that strives to customise care to the person affected person. “Nociscan’s distinctive biomarker analysis of every disc to tell the optimum remedy plan is an ideal match for my customized strategy to affected person analysis and care,” mentioned Dr. Karahalios. “The 2-year sturdy outcomes knowledge just lately printed within the European Backbone Journal that highlights how sufferers handled congruent with Nociscan outcomes achieved considerably higher outcomes than these whose remedy deviated from the Nociscan steering is a compelling basis of proof that I’m excited to contribute to by way of my KOL involvement with Aclarion.”
“We’re thrilled to be including one more world thought chief within the care of continual low again ache to the dedicated group of KOL’s which can be already pushing proof of Nociscan’s efficacy to the world,” mentioned Brent Ness, CEO of Aclarion. “Dr. Karahalios sits in a novel place main one of many largest spine care practices on the planet to assist articulate Nociscan’s worth proposition to key stakeholders within the worth chain. We’re happy to welcome Dr. Karahalios to Aclarion’s advisory group.”
Moreover, Aclarion will probably be attending the Worldwide Society for the Development of Backbone Surgical procedure (ISASS), June 1-3, 2023 in San Francisco, CA the place their well being economics outcomes summary will probably be offered. For details about ISASS 2023, please go to: https://isass.org/isass-2023/
About Aclarion, Inc.
Aclarion is a healthcare expertise firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize medical remedies. The Firm is first addressing the continual low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By means of a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers vital insights into the situation of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For extra data, please go to www.aclarion.com.
Ahead Trying Statements
This press launch accommodates forward-looking statements throughout the that means of the Personal Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934 in regards to the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic details, resembling “anticipates,” “believes” and “expects” or comparable expressions, are forward-looking statements. These forward-looking statements are based mostly on the present plans and expectations of administration and are topic to various uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra absolutely in our filings with the Securities and Trade Fee. Readers are inspired to overview the part titled “Threat Components” within the Firm’s Annual Report on Type 10-Ok for the 12 months ended December 31, 2022, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Trade Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not because of new data, future occasions or in any other case.
Kirin M. Smith
PCG Advisory, Inc.
Discussion about this post